Prognostic value of uric acid in heart failure: a meta-analysis
Hu Deng
Zhang Lijuan
Chen Xin
Wang Zhiquan
Abstract：Objectives We performed a Meta-analysis for published literatures to assess the value of uric acid in heart failure. Methods We searched literatures of PubMed, EMBASE, and The Cochrane Library and reference lists of relevant articles from inception to April 2018. Two investigators screened out the literature independently according to the inclusion and exclusion criteria, and then extracted relevant information and evaluated literature quality. Revman 5.2 software was used for conducting a Meta-analysis. Results Hyperuricemia is associated with poor prognosis in patients with HF. Elevated uric acid in patients with HF has a higher risk of composite ending events (HR=1.19, 95%CI: 1.14~1.25), all-cause mortality (HR=1.3, 95%CI: 1.21~1.40), cardiovascular mortality (HR=1.43, 95%CI: 1.05~1.93), and rehospitalization (HR=1.16, 95%CI: 1.07~1.26). Subgroup analysis shows that the effect of elevated serum uric acid on HF prognosis is significant irrespective of HF type, area, NYHA class, duration of follow-up and ejection fraction. While in the group which the percentage of the patients who used diuretic is less than 80%, there is no significant association between elevated uric acid and poor prognosis in HF patients (HR=1.40, 95%CI: 0.96~2.03). Conclusion Elevated uric acid is associated with poor prognosis in HF patients. The effect of prognosis is significant irrespective of HF type, area, NYHA class, duration of follow-up and ejection fraction. The use of diuretic may impact the prognostic value for uric acid in HF.
Keywords：Uric acidHeart failurePrognosisCohort studyMeta-analysis
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 400-403,409 )